Azaindole tyrosine kinase inhibitors

Details Azaindole tyrosine kinase inhibitors Azaindole tyrosine kinase inhibitors

2005-02-01

2005-02-01

Coleman, Brenda (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S113000

Reexamination Certificate

active

06849641

ABSTRACT:
The present invention relates to novel 3-hetero-arylideneazaindolin-2-one compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.

REFERENCES:
patent: 4002749 (1977-01-01), Rovnyak
patent: 4053613 (1977-10-01), Rovnyak et al.
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5719135 (1998-02-01), Buzzetti et al.
patent: 5721237 (1998-02-01), Myers et al.
patent: RE36256 (1999-07-01), Spada et al.
patent: 6147106 (2000-11-01), Tang et al.
patent: 6486185 (2002-11-01), McMahon et al.
patent: 6569868 (2003-05-01), Tang et al.
patent: 20030216462 (2003-11-01), Wei et al.
patent: 20040024010 (2004-02-01), Tang et al.
patent: 20040039196 (2004-02-01), Wei et al.
patent: 20040053924 (2004-03-01), Liang et al.
patent: 20040067531 (2004-04-01), Tang et al.
patent: 0 566 266 (1993-10-01), None
patent: 1398224 (1965-03-01), None
patent: 389992 (1992-12-01), None
patent: 9115495 (1991-10-01), None
patent: 9220642 (1992-11-01), None
patent: 9221660 (1992-12-01), None
patent: 9403427 (1994-02-01), None
patent: 9410202 (1994-05-01), None
patent: 9414808 (1994-07-01), None
patent: WO 95 14667 (1995-06-01), None
patent: WO 96 00226 (1996-01-01), None
patent: WO 96 22976 (1996-08-01), None
patent: WO 96 40116 (1996-12-01), None
patent: WO 98 07695 (1998-02-01), None
patent: WO 9910325 (1999-03-01), None
Beilstein, Reg. No. 252929 , L4 Answer 1 of 10 Copyright 1998 Beilstein CD&S.
Cance et al., “Novel Protein Kinases Expressed in Human Breast Cancer,”Int. J. Cancer54:571-577 (1993).
Fendly et al., “Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
eu Gene Product,”Cancer Research50:1550-1558 (1990).
Komada et al., “The Cell Dissociation and Motility Triggered by Scatter Factor/Hepatocyte Growth Factor are Mediated Through the Cytoplasmic Domain of the C-Met Receptor,”Oncogene8:2381-2390 (1993).
Sandberg-Nordqvist et al., “Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors,”Cancer Research53:2475-2478 (1993).
Akbasak and Sunar-Akbasak et al., “Oncogenes: cause or consequence in the development of glial tumors,”J. Neurol. Sci.111:119-133 (1992).
Andreani et al., “Synthesis and potentialcoanthracyclinicactivity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones,”Eur. J. Med. Chem.32:919-924 (1997).
Arteaga et al., “Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice,”J. Clin. Invest.84:1418-1423 (1989).
Baserga, “Oncogenes and the Strategy of Growth Factors,”Cell79:927-930 (1994).
Baserga, “The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?”Cancer Research55:249-252 (1995).
Biggs and Sykes, “Two Isomeric Homologues of Thiamine,”J. Chem. Soc.pp. 1849-1854 (1959).
Bolen et al., “The Src family of tyrosine protein kinases in hemopoietic signal transduction,”FASEB J.6:3403-3409 (1992).
Bolen, “Nonreceptor tyrosine protein kinases,”Oncogene8:2025-2031 (1993).
Bonner et al., “Strucuture and Biological Activity of Human Homologs of the raf/mil Oncogene,”Molecular and Cellular Biology5:1400-1407 (1985).
Coppola et al., “A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor,”Molecular and Cellular Biology14:4588-4595 (1994).
Daisley and Hanbali, “Synthesis of 5-Methyl and 7-Methyl-4-Azaindol-2(3H)-Ones,”Synth. Commun.5:53-57 (1975).
Daisley and Hanbali, “A Short Synthesis of 4- and 6-Azaindol-2(3H)-Ones,”Synth. Commun.11(9):743-749 (1981).
Decker and Lohmann-Matthes, “A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity,”J. Immunol. Methods15:61-69 (1988).
Dickson et al., “Tyrosine kinase receptor—nuclear protooncogene interactions in breast cancer,”Cancer Treatment Res.61:249-273 (1992).
Fantl et al., “Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways,”Cell69:413-423 (1992).
Fingl and Woodbury, “Chapter 1—General Priciples,” inThe Pharmacological Basis of Therapeutics5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975).
Floege et al., “Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo,”Kidney International43:S47-S54 (1993).
Goldring and Goldring, “Cytokines and Cell Growth Control,”Critical Reviews in Eukaryotic Gene Expression1:301-326 (1991).
Honegger et al., “Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing,”Cell51:199-209 (1987).
J. Amer. Chem. Soc.33:763 (1911).
Jellinek et al., “Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor,”Biochemistry33:10450-10456 (1994).
Kendall and Thomas, “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor,”Proc. Natl. Acad. Sci. USA90:10705-10709 (1993).
Kim et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo,”Nature362:841-844 (1993).
Kinsella et al., “Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel,”Exp. Cell Research199:56-62 (1992).
Koch et al., “SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins,”Science252:668-674 (1991).
Korc et al., “Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha,”J. Clin. Invest.90:1352-1360 (1992).
Korzeniewski and Callewaert, “An Enzyme-Release Assay for Natural Cytotoxicity1,”J. Immunol. Methods64:313-320 (1983).
Kumbae et al., “Amplification of α-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin,”Oncogene7:627-633 (1992).
Kumar et al., “Synthesis of 7-Azaindole and 7-Azaoxindole Derivatives through a Palladium-Catalyzed Cross-Coupling Reaction,”J. Org. Chem.57:6995-6998 (1992).
La Manna et al., “Sulla Sintesi Di 7-Azaossindoli 5-Sostituiti,”Boll. Chim. Farm.112:22-28 (1973) (In Spanish with English Abstract).
Lee and Donoghue, “Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction,”Journal of Cell Biology118:1057-1070 (1992).
Macauley et al., “Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells,”Cancer Research50:2511-2517 (1990).
Mariani et al., “Inhibition of angiogenesis by PCE 26806, a potent tyrosine kinase inhibitor,”Experimental Therapeutics—Proceedings of the American Association for Cancer Research35:381 at abstract No. 2268 (Mar. 1994).
Morrison et al., “Signal Transduction From Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increase Raf-1 Phosphorylation and Associated Protein Kinase Activity,”Proc. Natl. Acad. Sci. USA85:8855-8859 (1988).
Mosmann, “Rapid Colorimetric Assay for Cellular Growth and S

Affiliated with

Also associated with

Rating

Azaindole tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Azaindole tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azaindole tyrosine kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3484871